A survey on UK researchers' views regarding their experiences with the de-identification, anonymisation, release methods and re-identification risk estimation for clinical trial datasets.

IF 2.2 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Clinical Trials Pub Date : 2025-02-01 Epub Date: 2024-06-19 DOI:10.1177/17407745241259086
Aryelly Rodriguez, Steff C Lewis, Sandra Eldridge, Tracy Jackson, Christopher J Weir
{"title":"A survey on UK researchers' views regarding their experiences with the de-identification, anonymisation, release methods and re-identification risk estimation for clinical trial datasets.","authors":"Aryelly Rodriguez, Steff C Lewis, Sandra Eldridge, Tracy Jackson, Christopher J Weir","doi":"10.1177/17407745241259086","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There are increasing pressures for anonymised datasets from clinical trials to be shared across the scientific community. However, there is no standardised set of recommendations on how to anonymise and prepare clinical trial datasets for sharing, while an ever-increasing number of anonymised datasets are becoming available for secondary research. Our aim was to explore the current views and experiences of researchers in the United Kingdom about de-identification, anonymisation, release methods and re-identification risk estimation for clinical trial datasets.</p><p><strong>Methods: </strong>We used an online exploratory cross-sectional descriptive survey that consisted of both open-ended and closed questions.</p><p><strong>Results: </strong>We had 38 responses to invitation from June 2022 to October 2022. However, 35 participants (92%) used internal documentation and published guidance to de-identify/anonymise clinical trial datasets. De-identification, followed by anonymisation and then fulfilling data holders' requirements before access was granted (controlled access), was the most common process for releasing the datasets as reported by 18 (47%) participants. However, 11 participants (29%) had previous knowledge of re-identification risk estimation, but they did not use any of the methodologies. Experiences in the process of de-identifying/anonymising the datasets and maintaining such datasets were mostly negative, and the main reported issues were lack of resources, guidance, and training.</p><p><strong>Conclusion: </strong>The majority of responders reported using documented processes for de-identification and anonymisation. However, our survey results clearly indicate that there are still gaps in the areas of guidance, resources and training to fulfil sharing requests of de-identified/anonymised datasets, and that re-identification risk estimation is an underdeveloped area.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":"22 1","pages":"11-23"},"PeriodicalIF":2.2000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809122/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17407745241259086","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There are increasing pressures for anonymised datasets from clinical trials to be shared across the scientific community. However, there is no standardised set of recommendations on how to anonymise and prepare clinical trial datasets for sharing, while an ever-increasing number of anonymised datasets are becoming available for secondary research. Our aim was to explore the current views and experiences of researchers in the United Kingdom about de-identification, anonymisation, release methods and re-identification risk estimation for clinical trial datasets.

Methods: We used an online exploratory cross-sectional descriptive survey that consisted of both open-ended and closed questions.

Results: We had 38 responses to invitation from June 2022 to October 2022. However, 35 participants (92%) used internal documentation and published guidance to de-identify/anonymise clinical trial datasets. De-identification, followed by anonymisation and then fulfilling data holders' requirements before access was granted (controlled access), was the most common process for releasing the datasets as reported by 18 (47%) participants. However, 11 participants (29%) had previous knowledge of re-identification risk estimation, but they did not use any of the methodologies. Experiences in the process of de-identifying/anonymising the datasets and maintaining such datasets were mostly negative, and the main reported issues were lack of resources, guidance, and training.

Conclusion: The majority of responders reported using documented processes for de-identification and anonymisation. However, our survey results clearly indicate that there are still gaps in the areas of guidance, resources and training to fulfil sharing requests of de-identified/anonymised datasets, and that re-identification risk estimation is an underdeveloped area.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Trials
Clinical Trials 医学-医学:研究与实验
CiteScore
4.10
自引率
3.70%
发文量
82
审稿时长
6-12 weeks
期刊介绍: Clinical Trials is dedicated to advancing knowledge on the design and conduct of clinical trials related research methodologies. Covering the design, conduct, analysis, synthesis and evaluation of key methodologies, the journal remains on the cusp of the latest topics, including ethics, regulation and policy impact.
期刊最新文献
Evaluating the use of text-message reminders and personalised text-message reminders on the return of participant questionnaires in trials, a systematic review and meta-analysis. Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study. From RAGs to riches: Utilizing large language models to write documents for clinical trials. Hybrid sample size calculations for cluster randomised trials using assurance. Characterization of studies considered and required under Medicare's coverage with evidence development program.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1